BioWorld International articles from November 2005

BioWorld International archives from November 2005

CAT, Abbott settle Humira dispute: Abbott pays $255m.
November 9, 2005... Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. At issue was the royalty rate expected for sales of the rheumatoid...

2005's second German IPO prices at low end of range.
November 9, 2005... MUNICH, Germany -- Jerini AG went public this week in Germany's first biotech initial public offering since Paion, of Aachen, tested the markets in January. Berlin-based Jerini expected to raise about 61 million [euro] (US$73.2 million),...

Map of changes promises to unmask multitude of genes.
November 9, 2005... LONDON -- While the Human Genome Project documented the 99.9 percent of the genome that is common to all of us, the International HapMap Project--which published the results of its first phase in Nature last week--has charted the places in the...

NicOx licenses respiratory drug to Topigen for 54.9m [euro].
November 9, 2005... In its sixth collaboration to date, NicOx SA entered a potential 54.9 million [euro] (US$66.6 million) deal with Topigen Pharmaceuticals Inc. for rights to NicOx's Phase IIa compound, NCX 1020, in chronic obstructive pulmonary disease (COPD)...

CAT paying $14m in shares for genencor cancer drugs.
November 9, 2005... LONDON -- Just days after Cambridge Antibody Technology Group plc said it settled its long-standing feud with Abbott Laboratories over Humira royalty payments, the firm picked up the clinical portfolio of Genencor International Inc. for $14...

Ark's gene therapy product Cerepro under review in EU.
November 9, 2005... LONDON -- Ark Therapeutics Group plc is ahead in the race to be first with an approved gene therapy product outside China, after Cerepro, for treating malignant melanoma, was accepted for review in Europe. The news followed approval a week...

Abcam plc.(Other News To Note)(Brief Article)
November 9, 2005... Abcam plc, of Cambridge, UK completed its listing on the Alternative Investment Market in London, raising 15.25 million [pounds sterling] (US$27. 1 million). The company placed nearly 6 million new shares, or 26.5 percent of the enlarged share...

Ardana plc.(Other News To Note)(Brief Article)
November 9, 2005... Ardana plc, of Edinburgh, UK, announced positive results in the second Phase I trial of a testosterone cream for treating male hypogonadism, formulated with the company's proprietary delivery technology. The study in healthy female subjects...

Bill & Melinda Gates Foundation.(Other News To Note)(Brief Article)
November 9, 2005... Bill & Melinda Gates Foundation awarded $50.7 million to the Liverpool School of Tropical Medicine to fund research in infectious and tropical diseases, including malaria. The research will be carried out at a new center for Tropical and...

BrainStorm Cell Therapeutics.(Other News To Note)
November 9, 2005... BrainStorm Cell Therapeutics, of New York and Tel Aviv, Israel, said its human bone marrow derived GDNF-expressing stem cells implanted into rodent models of Parkinson's disease improved motor function within two weeks of the single injection,...

AM-Pharma gets 9m [euro] in first closing of series B round.
November 9, 2005... AM-Pharma BV raised 9 million [euro] (US$10.8 million) in a Series B round to progress three clinical programs involving two drug candidates. The company, based in Bunnik, the Netherlands, needed just two investors to raise the cash....

CeNeS Pharmaceuticals.(Other News To Note)
November 9, 2005... CeNeS Pharmaceuticals, of Cambridge, UK, said Molecular Psychiatry published a paper this week that further supports the hypothesis that a catechol-O-methyl-transferase (COMT) inhibitor that acts in the brain would be a useful agent to address...

Cenix BioScience GmbH.(Other News To Note)
November 9, 2005... Cenix BioScience GmbH, of Dresden, Germany, entered an agreement with Berlin-based Schering AG to extend their target validation partnership, following the completion of a pilot project started late last year. The pilot project focused on the...

Covalys Biosciences AG.(Other News To Note)
November 9, 2005... Covalys Biosciences AG, of Witterswil, Switzerland, launched its products for "mix and read" protein interaction assays and for pull-down experiments based on its SNAP-tag. These SNAP-vitro HTRF products were developed to facilitate the...

Cyprotex plc.(Other News To Note)(Brief Article)
November 9, 2005... Cyprotex plc, of Macclesfield, UK, said Drug Metabolism and Disposition published details of its virtual human and rat system called Cloe PK. The results show how the technology can estimate blood levels of new drugs without the use of animals....

Domantis Ltd.(Other News To Note)
November 9, 2005... Domantis Ltd., of Cambridge, UK, and Argenta Discovery of Harlow, UK, said they have demonstrated the in vivo efficacy of a human domain antibody (dAb) in an animal model of chronic obstructive pulmonary disease. Inhalation of a dAb against an...

Epistem Ltd.(Other News To Note)
November 9, 2005... Epistem Ltd., of Manchester, UK, an epithelial and adult stem cell services company, raised about 1.7 million [pounds sterling] (US$3.1 million) in a private placing to invest in progressing novel therapies and to secure and promote its...

Flamel Technologies SA.(Other News To Note)
November 9, 2005... Flamel Technologies SA, of Lyon, France, said its partner, London-based GlaxoSmithKline plc obtained successful Phase III trial results on a controlled-release formulation of an already-marketed GSK drug using Flamel's Micropump technology....

Genome Express SA.(Other News To Note)
November 9, 2005... Genome Express SA, of Grenoble, France, signed a three-way agreement with two French organizations, the Centre Leon Berard in Lyon and the Centre Jean Perrin in Clermont Ferrand, to conduct the Mutacancer research program. Mutacancer is a...

Genus plc, of Nantwich, UK, agreed to take over its counterpart Sygen International plc, of Kingston Bagpuize, UK, in a cash offer valuing Sygen at 187 million [pounds sterling] (US$332.4 million).(Other News To Note)
November 9, 2005... Genus plc, of Nantwich, UK, agreed to take over its counterpart Sygen International plc, of Kingston Bagpuize, UK, in a cash offer valuing Sygen at 187 million [pounds sterling] (US$332.4 million). Genus is offering 63.2 pence per share, a...

Norway.(Other News To Note)(Brief Article)
November 9, 2005... Norway and the UK agreed to pool information from two child health studies, along with information from the two countries' Biobanks, to further research in childhood diseases including attention deficit disorder, diabetes and schizophrenia. The...

Opal Therapeutics Inc.(Other News To Note)(Brief Article)
November 9, 2005... Opal Therapeutics Inc., of Melbourne, Australia, raised $6 million in a Series A financing led by GBS Venture Partners. Also participating were Alloy Ventures, Alta Partners and Uniseed. The funds will be used to extend the company's...

PacMab Ltd.(Other News To Note)
November 9, 2005... PacMab Ltd., of Sydney, Australia, plans to raise funds to commercialize its treatment for a fatal blood cancer and for other blood disorders by listing its shares in December on the Australian Stock Exchange. The company plans to raise a...

Phoqus Group plc.(Other News To Note)
November 9, 2005... Phoqus Group plc, of West Malling, UK, completed its initial public offering on the Alternative Investment Market in London, raising 10 million [pounds sterling] (US$17.8 million). The drug delivery company placed 7.1 million new shares, bring...

Physiomics plc.(Other News To Note)
November 9, 2005... Physiomics plc, of Oxford, UK said it has developed an addition to its core systems biology cell growth model that can show why different cancer cells respond in different ways to aurora kinase inhibitors. There are some 16 aurora kinase...

pSivida Ltd.(Other News To Note)(Brief Article)
November 9, 2005... pSivida Ltd., of Perth, Australia, began a Phase IIb trial of BrachySil, a potential brachytherapy treatment for inoperable primary liver cancer, at Singapore General Hospital. The study also will evaluate pSivida's SIMPL, a fine-gauge needle,...

Regenera Ltd.(mergers with Advanced Ocular Systems Inc.)(Brief Article)
November 9, 2005... Regenera Ltd., of Perth, Australia, said it will merge with Massachusetts-based Advanced Ocular Systems (AOS) Inc. to enhance its portfolio of ophthalmic products and technologies. Subject to stockholder approval, Regenera will acquire all of...

Reneuron Group plc.(Other News To Note)(Brief Article)
November 9, 2005... Reneuron Group plc, of Guildford, UK, developed human hepatocyte cell lines using its c-mycER platform technology. The cell lines have been shown to express a range of adult human liver functional markers, indicating their potential value as a...

Sareum Holdings plc.(Other News To Note)
November 9, 2005... Sareum Holdings plc, of Cambridge, UK agreed to a collaboration with Schering AG, of Berlin, Germany, to provide protein structure determination capabilities. Sareum will use high-throughput protein expression, purification and structure...

SciGen Ltd.(Other News To Note)
November 9, 2005... SciGen Ltd., of Sydney, Australia, said its two largest shareholders, SciTech Genetics Pte. Ltd., of Singapore, and Warsaw, Poland-based Bioton, entered a share exchange agreement, which could result in Bioton gaining 44.7 percent equity in...

Sinovac Biotech Ltd.(Other News To Note)
November 9, 2005... Sinovac Biotech Ltd., of Beijing, said the FDA issued a Good Manufacturing Practices (GMP) certificate for its influenza vaccine, Anflu, which marks the final approval required to sell Anflu in China. The Anflu vaccine is a modern split...

UCB SA.(Other News To Note)
November 9, 2005... UCB SA, of Brussels, Belgium, said a single 400-mg injection of Cimzia (certolizumab pegol, CDP 870) every four weeks was effective in maintaining control of the signs and symptoms of Crohn's disease following induction therapy, according to...

University of Strathclyde, UK, sold the remaining 19 percent stake in its spin-out company, ProPharma Ltd., to the majority shareholder, Evotec AG, of Hamburg, Germany.(Other News To Note)
November 9, 2005... University of Strathclyde, UK, sold the remaining 19 percent stake in its spin-out company, ProPharma Ltd., to the majority shareholder, Evotec AG, of Hamburg, Germany. ProPharma, which provides drug manufacturing and formulation services, was...

ExonHit launches 6.5m [euro] IPO on Alternext market.
November 9, 2005... PARIS -- ExonHit Therapeutics SA launched an initial public offering on the Alternext market of the Euronext stock exchange in Paris Nov. 8, hoping to raise 6.5 million [euro] (US$7.6 million). Paris-based ExonHit is increasing its capital...

Raising drug prices in Europe suggested as solution for U.S.(BIO-Europe 2005)
November 9, 2005... DRESDEN, Germany -- Drug prices in Europe should rise to be more reflective of the real cost of developing them, allowing prices to fall in the U.S., said Jim Greenwood, president of the Biotechnology Industry Organization. "The U.S. is...

Molecular mimic could lead to new immunotherapeutics.
November 9, 2005... LONDON -- An artificial molecule that can activate a cell-surface receptor that plays a key role in coordinating immune responses could one day lead to new treatments to help fight infections. Ultimately, researchers also hope to develop the...

DOR buying Gastrotech for $39m in shares, milestones.
November 9, 2005... Pulling in two more gastrointestinal drug candidates, DOR BioPharma Inc. signed a letter of intent to acquire Danish biotechnology company Gastrotech Pharma A/S for $9 million in shares and up to $30 million in milestone payments. As...

Fovea brings in $25m for retinal disease research.(Company Profile)
November 9, 2005... Bringing together experts in the field of retinal diseases, the new Paris-based company Fovea Pharmaceuticals SA closed a 20.5 million [euro] (US$25 million) Series A financing round. Founded in May, the company plans to use the proceeds to...

Ariana signs with Pasteur Institute, picks up funding.(Ariana Pharmaceuticals )
November 9, 2005... PARIS -- Ariana Pharmaceuticals signed three agreements with the Pasteur Institute that tie the company's future to the Paris-based medical research foundation. Through the deal, the Pasteur Institute acquired a shareholding in Ariana, the...

Affectis Pharmaceuticals AG.(Other News To Note)
November 9, 2005... Affectis Pharmaceuticals AG, of Munich, Germany, entered a collaboration to apply its technology and preclinical models for the validation of depression and anxiety gene targets that belong to NV Organon, of Oss, the Netherlands. Financial...

Affibody AB, of Stockholm, Sweden, and Asahi Kasei Corp., of Fuji, Japan, agreed to develop a product aimed at enabling the selective removal of a target molecule from fluid mixtures.(Other News To Note)
November 9, 2005... Affibody AB, of Stockholm, Sweden, and Asahi Kasei Corp., of Fuji, Japan, agreed to develop a product aimed at enabling the selective removal of a target molecule from fluid mixtures. Terms call for Affibody to create a molecule that will be...

Antisoma Group plc.(Other News To Note)
November 9, 2005... Antisoma Group plc, of London, presented data on AS1404, a vascular disruption agent, at the European Cancer Conference in Paris last week. New tests have studied the compound's ability to selectively damage blood vessels in tumors, by...

Arakis Ltd.(Other News To Note)(Brief Article)
November 9, 2005... Arakis Ltd., of Little Chesterford, UK, completed Phase I single and multidose studies of AD337, an enantiomer of an approved non-opioid analgesic for the treatment of fibromyalgia syndrome. Preparations now are under way for Phase II...

Ark Therapeutics Group plc.(Other News To Note)
November 9, 2005... Ark Therapeutics Group plc, of London, was awarded a grant of 2.2 million [euro] (US$2.6 million) toward the construction of a GMP manufacturing facility for producing gene therapy products. The facility is situated in Kuopio, Finland, and the...

Vernalis paying Mylan $23m for U.S. rights to Apokyn.
November 9, 2005... LONDON -- Vernalis plc acquired U.S. rights to Apokyn, a marketed orphan drug for treating late-stage symptoms of Parkinson's disease from Mylan Laboratories Inc., for $23 million, and agreed to collaborate on new formulations of the drug with...

Bioxell SpA.(Other News To Note)(Brief Article)
November 9, 2005... Bioxell SpA, of Milan, Italy, moved BXL682, a vitamin D3 analogue, into a Phase IIa trial in non-bacterial prostatitis. The compound already is undergoing a Phase IIb clinical trial in benign prostatic hyperplasia. The additional study will...

CellCentric Ltd.(Other News To Note)
November 9, 2005... CellCentric Ltd., of Cambridge, UK, formed a research collaboration with Professor Chris Boshoff of the Wolfson Institute of Biomedical Research, University College London. The program will explore epigenetic-related cancer cell targets,...

ChemDiv Inc., of San Diego, entered an agreement with ProQinase GmbH, of Freiburg, Germany, on new kinase inhibitors.(Other News To Note)(Brief Article)
November 9, 2005... ChemDiv Inc., of San Diego, entered an agreement with ProQinase GmbH, of Freiburg, Germany, on new kinase inhibitors. ChemDiv will support design and synthesis of target-focused small-molecule libraries, undertake medicinal chemistry for...

Covalys Biosciences AG.(Other News To Note)
November 9, 2005... Covalys Biosciences AG, of Witterswil, Switzerland, and the Ecole Polytechnique Federale de Lausanne formed an agreement allowing Covalys to exclusively commercialize the ACP-tag technology. ACP-tag is suited for experiments with membrane...

Epigenomics AG.(Other News To Note)(Brief Article)
November 9, 2005... Epigenomics AG, of Berlin, reported that results of its Tamoxifen treatment response test study were inconclusive. Following the timely completion of a blinded test study for its response test, the candidate markers could not be validated...

Evotec AG.(Other News To Note)(research agreement with Boehringer Ingelheim GmbH)(Brief Article)
November 9, 2005... * Evotec AG, of Hamburg, Germany, said that Boehringer Ingelheim GmbH, of Ingelheim, Germany, extended the scope of their collaboration to identify and develop therapeutics acting on G protein-coupled receptors. Boehringer research sites in...

NicOx SA.(Other News To Note)
November 9, 2005... NicOx SA, of Sophia Antipolis, France, extended its research collaboration agreement with Merck & Co. Inc., of Whitehouse Station, N.J., originally formed in August 2003 to evaluate nitric oxide-donating compounds in an undisclosed therapeutic...

Oxford BioMedica plc.(Other News To Note)
November 9, 2005... Oxford BioMedica plc, of Oxford, UK, said it was looking to raise 20 million [pounds sterling] (US$35.3 million) to 30 million [pounds sterling] to finance a Phase III trial of its cancer gene therapy product TroVax. That dropped the company's...

Prana Biotechnology Ltd.(Other News To Note)
November 9, 2005... Prana Biotechnology Ltd., of Melbourne, Australia, completed a Phase I trial of PBT2, showing that the Alzheimer's disease compound was well tolerated with little difference in the incidence of adverse events between those receiving PBT2 and...

Santaris Pharma A/S.(Other News To Note)
November 9, 2005... Santaris Pharma A/S, of Horsholm, Denmark, received FDA approval for an investigational new drug application to commence a Phase I/II study of its locked nucleic acid (LNA) drug candidate, SPC2996, in chronic lymphocytic leukemia (CLL). SPC2996...

Santhera Pharmaceuticals AG.(Other News To Note)
November 9, 2005... Santhera Pharmaceuticals AG, of Liestal, Switzerland, started a collaborative clinical trial with the U.S. National Institutes of Neurological Disorder and Stroke at the National Institutes of Health to evaluate SNT-MC17 (idebenone) in patients...

SkyePharma plc.(Other News To Note)
November 9, 2005... SkyePharma plc, of London, agreed to a Japanese marketing deal for DepoBupivacaine, a sustained-release formulation of bupivacaine, with Maruho and Co. Ltd. Maruho will pay up $18 million, including up-front and milestone payments, and will...

UK BioIndustry Association.(Other News To Note)
November 9, 2005... UK BioIndustry Association said Simon Best will be its new chairman as of January. Best, Chairman of the reproductive health company Ardana plc, of Edinburgh, replaces David Chiswell, who steps down after three years.

IDM initiating third Phase II trial of Uvidem in melanoma.
November 16, 2005... PARIS -- IDM Pharma Inc. initiated another Phase II trial of its therapeutic vaccine Uvidem, which it is developing in collaboration with Sanofi-Aventis for the treatment of melanoma. The trial will involve 50 patients with resected stage...

As industry changes, so does investing criterion.
November 16, 2005... DRESDEN, Germany -- It used to be that the second recruit to a biotech start-up was the chief financial officer, but in these product-obsessed times, the second name on the corporate roster is development director. "Today, early stage...

New oncogene regulation information locates target.
November 16, 2005... LONDON -- A team of European researchers identified an enzyme that helps to activate one of the most important oncogenes in human tumors. The molecule could, the researchers predicted, form a potential new target for cancer chemotherapy. ...

Korea touts itself as growth region for biotech investing.(BIO-Europe 2005)
November 16, 2005... DRESDEN, Germany -- South Korea (the Republic of Korea, if you will) had a near-ubiquitous presence during last week's BIO-Europe 2005 conference at this historic city's International Congress Center. In addition to having the most...

SkyePharma approached, initiates strategic review.
November 16, 2005... LONDON -- SkyePharma plc said it has ordered a strategic review of the business after receiving an "unsolicited approach" from a third party. In the light of that, the London-based drug delivery company has decided to "review all of its...

Acambis plc, of Cambridge, UK, agreed to a marketing and manufacturing deal with Bharat Biotech International Ltd., of Hyderabad, India, for its ChimeriVax-JE vaccine against Japanese encephalitis (JE).(Other News To Note)
November 16, 2005... Acambis plc, of Cambridge, UK, agreed to a marketing and manufacturing deal with Bharat Biotech International Ltd., of Hyderabad, India, for its ChimeriVax-JE vaccine against Japanese encephalitis (JE). Bharat will be responsible for end-stage...

Affibody AB.(Other News To Note)
November 16, 2005... Affibody AB, of Stockholm, Sweden, entered a cooperative agreement with the National Cancer Institute in Bethesda, Md., which builds on the company's Affibody technology and various conjugation systems of the National Institutes of Health. The...

Angel Biotechnology Holding plc.(Other News To Note)
November 16, 2005... Angel Biotechnology Holdings plc, of Newcastle, UK, raised 1.5 million [pounds sterling] (US$2.6 million) in a listing on the Alternative Investment Market in London, valuing the protein manufacturing company at [pounds sterling]6.62 million....

Antisoma plc.(Other News To Note)
November 16, 2005... Antisoma plc, of London, presented new data on the mechanism of action of AS1404, a vascular disrupting agent in Phase II for treating non-small-cell lung cancer, showing it increases the levels of various cytokines.

Ardana plc, of Edinburgh, UK, granted Pharmacuro ApS, of Denmark, exclusive rights to market Striant.(Other News To Note)
November 16, 2005... Ardana plc, of Edinburgh, UK, granted Pharmacuro ApS, of Denmark, exclusive rights to market Striant, Ardana's testosterone-replacement therapy for male hypogonadism, in the Nordic region of Europe. Pharmacuro expects to launch Striant at the...

Avexa Ltd.(collabrates with Commonwealth Scientific and Industrial Research Organization)(Brief Article)
November 16, 2005... Avexa Ltd., of Victoria, Australia, entered a collaboration with the Commonwealth Scientific and Industrial Research Organization (CSIRO), Australia's national research agency, to discover drugs for the treatment of viral diseases. As part of...

BioInvent International AB.(Other News To Note)
November 16, 2005... BioInvent International AB, of Lund, Sweden, said results from animal tests involving its drug candidate, BI-204, for the treatment of atherosclerosis showed that the drug impedes plaque formation and reduced the size of plaques that already...

Cryptome Pharmaceuticals Ltd.(Other News To Note)
November 16, 2005... Cryptome Pharmaceuticals Ltd., of Melbourne, Australia, said it will receive more than A$850,000 (US$623,361) from Dairy Australia over the next three years to conduct research that could identify and characterize proteins and fragments of...

Cyclacel Group plc.(Other News To Note)
November 16, 2005... Cyclacel Group plc, of Dundee, UK, said CYC116, an orally available aurora kinase inhibitor, entered preclinical development as its third development candidate. The product has demonstrated anticancer activity in solid tumor and hematological...

DeCode Genetics Inc.(Other News To Note)
November 16, 2005... DeCode Genetics Inc., of Reykjavik, Iceland, said a paper by a team of its scientists showed the discovery of a gene variant conferring increased risk of myocardial infarction. The link between the variant of the gene encoding the leukotriene...

D-Pharm.(Other News To Note)
November 16, 2005... D-Pharm, of Rehovot, Israel, reported interim results from the ongoing Phase II study of its neuroprotective agent DP-b99 in acute stroke patients. DP-b99 is a neuroprotective drug that addresses the array of damaging processes occurring in the...

Evotec AG.(Other News To Note)
November 16, 2005... Evotec AG, of Hamburg, Germany, started a Phase I trial with EVT 101, its NR2B subtype selective NMDA receptor antagonist for the potential treatment of Alzheimer's disease, neuropathic pain and Parkinson's disease. The study is a double-blind,...

Gen Tel BioSurfaces Inc.(Other News To Note)
November 16, 2005... GenTel BioSurfaces Inc., of Madison, Wis., said it partnered with Taiwan-based Abnova Corp. to combine Abnova's high-throughput protein and antibody content manufacturing capabilities with GenTel's multiplex immunoassay development service....

GPC Biotech AG.(Other News To Note)
November 16, 2005... GPC Biotech AG, of Martinsried, Germany, received clearance from the Paul-Erhlich-Institut to initiate clinical testing in Germany with the 1D09C3 cancer monoclonal antibody. The study is an open-label, Phase I trial evaluating 1D09C3 in...

GW Pharmaceuticals plc.(Other News To Note)
November 16, 2005... GW Pharmaceuticals plc, of Salisbury, UK, said Rheumatology published the first study of the use of its cannabis-based medicine, Sativex, in rheumatoid arthritis. The study showed the sublingual spray has a statistically significant effect in...

Hybrigenics SA.(Other News To Note)
November 16, 2005... Hybrigenics SA, of Paris, appointed Remi Delansorne CEO and Daan Ellens chairman. The appointments follow the death earlier this year of Bart Kwist, president and CEO. Delansorne previously was vice president for R&D at Hybrigenics. Ellens has...

iQur Ltd.(raises funds)(Brief Article)
November 16, 2005... iQur Ltd., of Southampton, UK, raised 2.6 million [pounds sterling] (US$4.5 million) in its third-round funding for the development of its diagnostics for hepatitis C and liver fibrosis. At the same time, the company (formerly known as HepCgen)...

Isogenica Ltd., of Cambridge, UK, agreed to use its CIS display technology to identify peptide candidates against targets from Amgen Inc., of Thousand Oaks, Calif.(Other News To Note)
November 16, 2005... Isogenica Ltd., of Cambridge, UK, agreed to use its CIS display technology to identify peptide candidates against targets from Amgen Inc., of Thousand Oaks, Calif. Isogenica will receive research fees and could get milestones and royalties.

Karo Bio.(Other News To Note)
November 16, 2005... Karo Bio, of Huddinge, Sweden, carried out a new share issue with preferential rights for its shareholders generating MSEK 279 before transaction costs. The cash gives the company an opportunity to take its projects further in clinical...

NicOx SA.(Other News To Note)
November 16, 2005... NicOx SA, of Sophia-Antipolis, France, said a Phase II trial of NCX 4016 in peripheral arterial obstructive disease (PAOD) did not meet its primary endpoint, having failed to show a statistically significant advantage in relation to placebo...

Pharmaxis Ltd.(Other News To Note)
November 16, 2005... Pharmaxis Ltd., of Sydney, Australia, completed its fund raising with gross proceeds of A$87 million (US$63 million) through the sale of 39.4 million shares. Of those shares, 1.3 million were American depository shares issued to U.S....